HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Quetiapine monotherapy in adolescents with bipolar disorder comorbid with conduct disorder.

Abstract
Bipolar Disorders (BD) are often comorbid with disruptive behaviour disorders (DBDs) (oppositional-defiant disorder or conduct disorder), with negative implications on treatment strategy and outcome. The aim of this study was to assess the efficacy of quetiapine monotherapy in adolescents with BD comorbid with conduct disorder (CD). A consecutive series of 40 adolescents (24 males and 16 females, age range 12-18 years, mean age 14.9 ± 2.0 years), diagnosed with a clinical interview (Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children-Present and Lifetime Version [K-SADS-PL]) according to American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria were included. All the patients were treated with quetiapine monotherapy (mean final dose 258 ± 124 mg/day, range 100-600 mg/day). At the end-point (3 months), 22 patients (55.0%) were responders (Clinical Global Impressions-Improvement [CGI-I] score of 1 or 2 and CGI-Severity [CGI-S] ≤ 3 and improvement of at least 30% Children's Global Assessment Scale [C-GAS] during 3 consecutive months). Both CGI-S and C-GAS significantly improved (p<0.0001). Nine out of the 16 patients with suicidality (56.3%) had a reduction in this severe symptom during the follow-up. Nonresponders were more frequently males, and more frequently had an attention-deficit/hyperactivity disorder (ADHD) comorbidity. Eight patients (20.0%) experienced moderate to severe sedation and eight (20.0%) experienced increased appetite and weight gain. In these severely impaired adolescents, quetiapine monotherapy was well tolerated and effective in>50% of the patients.
AuthorsGabriele Masi, Simone Pisano, Chiara Pfanner, Annarita Milone, Azzurra Manfredi
JournalJournal of child and adolescent psychopharmacology (J Child Adolesc Psychopharmacol) Vol. 23 Issue 8 Pg. 568-71 (Oct 2013) ISSN: 1557-8992 [Electronic] United States
PMID24138010 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Antipsychotic Agents
  • Dibenzothiazepines
  • Quetiapine Fumarate
Topics
  • Adolescent
  • Antipsychotic Agents (adverse effects, therapeutic use)
  • Attention Deficit Disorder with Hyperactivity (complications, drug therapy)
  • Bipolar Disorder (complications, drug therapy)
  • Child
  • Conduct Disorder (complications, drug therapy)
  • Dibenzothiazepines (adverse effects, therapeutic use)
  • Female
  • Humans
  • Male
  • Quetiapine Fumarate
  • Suicidal Ideation
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: